comprehensive -WSS

comprehensive

author：focus 2025-09-29 22:38:07 - browse：2

ASH19 CAR-T — Victor Segura Ibarra and Rita Serda, Ph.D., NCI, NIH

The Food and Drug Administration on Wednesday approved a futuristic new approach to treating cancer, clearing a Novartis therapy that has produced unprecedented results in patients with a rare and deadly cancer. The price tag: $475,000 for a course of treatment.

That sounds staggering to many patients — but it’s far less than analysts expected.

The therapy, called a CAR-T, is made by harvesting patients’ white blood cells and rewiring them to home in on tumors. Novartis’s product is the first CAR-T therapy to come before the FDA, leading a pack of novel treatments that promise to change the standard of care for certain aggressive blood cancers.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： Connecting traumatic brain injury and domestic violence

focus

WSS

A new study asks: Are we harming blood donors by taking blood?

Listen: PBM conflicts, RSV vaccines, & the future of flu season

New case study details death in closely watched Alzhiemer's trial

Can food be medicine? And other questions about a new push

When is a doctor not a doctor? Try when patients address women doctors

New case study details death in closely watched Alzhiemer's trial

hotspot

comprehensive

focus

Psychedelics group wrestles with new pharma identity

Inside the fall of star MIT scientist David Sabatini

DIEP, the 'gold standard' of breast reconstruction, is under threat

New oral drug delivery patch is modeled after octopus tentacles

Virginia high school admissions case could be legal follow

IVG is promising — but it won’t replace IVF quite yet

Psychedelics group wrestles with new pharma identity

Nobel honors Karikó and Weissman's enduring partnership

Trump demands the U.S. pay no more for drugs than other countries … again

Flu, Covid vaccination rates decline, new survey data show

leisure time

Bacterial infection may be ‘key event’ in endometriosis, study says

Russia says it foiled Ukrainian drone attack on Moscow as Kyiv's counteroffensive grinds on

Medicare innovation center doesn’t save money, experts say

A new study asks: Are we harming blood donors by taking blood?

Did the public have the right to know Arthur Ashe had AIDS?

A new study asks: Are we harming blood donors by taking blood?

leisure time

focus

hotspot

hotspot